Chapters

Transcript

Video

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Christian Ruff, MD

Christian Ruff, MD

Christian Ruff, MD
Principal Investigator, ENGAGE-AF Trial
TIMI Group
Director, General Cardiology
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA